NASDAQ: TNYA
Tenaya Therapeutics Inc Stock

$1.20+0.25 (+26.32%)
Updated Feb 14, 2025
TNYA Price
$1.20
Fair Value Price
$0.45
Market Cap
$95.06M
52 Week Low
$0.86
52 Week High
$7.01
P/E
-0.83x
P/B
0.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$117.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$94M
Beta
1.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TNYA Overview

Tenaya Therapeutics Incorporated is a biotechnology company that develops heart diseases therapies in the U.S. It uses cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic Hypertrophic Cardiomyopathy, and TN-301, a small molecule inhibitor of Histone Deacetylase 6 (HDAC6i) for use in heart gFailure with preserved ejection fraction (HFpEF), as well as genetic Dilated Cardiomyopathy (gDCM). The company was incorporated in 2016 and is headquartered in San Francisco, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TNYA's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TNYA
Ranked
#469 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TNYA news, forecast changes, insider trades & much more!

TNYA News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TNYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TNYA ($1.20) is overvalued by 166.24% relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TNYA ($1.20) is not significantly undervalued (166.24%) relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TNYA due diligence checks available for Premium users.

Valuation

TNYA fair value

Fair Value of TNYA stock based on Discounted Cash Flow (DCF)

Price
$1.20
Fair Value
$0.45
Overvalued by
166.24%
TNYA ($1.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TNYA ($1.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TNYA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.83x
Industry
-169.22x
Market
37.91x

TNYA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.84x
Industry
4.77x
TNYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TNYA's financial health

Profit margin

Revenue
$0.0
Net Income
-$25.6M
Profit Margin
0%
TNYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$140.6M
Liabilities
$28.0M
Debt to equity
0.25
TNYA's short-term assets ($85.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNYA's short-term assets ($85.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.8M
Investing
-$30.1M
Financing
$31.0k
TNYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TNYA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TNYAD$95.06M+26.72%-0.83x0.84x
CUEC$94.39M+4.93%-1.64x3.72x
SKYED$95.87M+3.27%5.96x1.26x
VORD$94.08M+3.01%-0.84x1.29x
ACOG$93.65M+5.42%N/A-32.08x

Tenaya Therapeutics Stock FAQ

What is Tenaya Therapeutics's quote symbol?

(NASDAQ: TNYA) Tenaya Therapeutics trades on the NASDAQ under the ticker symbol TNYA. Tenaya Therapeutics stock quotes can also be displayed as NASDAQ: TNYA.

If you're new to stock investing, here's how to buy Tenaya Therapeutics stock.

What is the 52 week high and low for Tenaya Therapeutics (NASDAQ: TNYA)?

(NASDAQ: TNYA) Tenaya Therapeutics's 52-week high was $7.01, and its 52-week low was $0.86. It is currently -82.88% from its 52-week high and 39.37% from its 52-week low.

How much is Tenaya Therapeutics stock worth today?

(NASDAQ: TNYA) Tenaya Therapeutics currently has 79,220,516 outstanding shares. With Tenaya Therapeutics stock trading at $1.20 per share, the total value of Tenaya Therapeutics stock (market capitalization) is $95.06M.

Tenaya Therapeutics stock was originally listed at a price of $15.35 in Jul 30, 2021. If you had invested in Tenaya Therapeutics stock at $15.35, your return over the last 3 years would have been -92.18%, for an annualized return of -57.24% (not including any dividends or dividend reinvestments).

How much is Tenaya Therapeutics's stock price per share?

(NASDAQ: TNYA) Tenaya Therapeutics stock price per share is $1.20 today (as of Feb 14, 2025).

What is Tenaya Therapeutics's Market Cap?

(NASDAQ: TNYA) Tenaya Therapeutics's market cap is $95.06M, as of Feb 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tenaya Therapeutics's market cap is calculated by multiplying TNYA's current stock price of $1.20 by TNYA's total outstanding shares of 79,220,516.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.